Antisense raises $5 million
Friday, 22 August, 2003
Drug discovery biotech Antisense Therapeutics (ASX:ANP) has added AUD$5 million to its coffers with the placement of 38.5 million new shares to the institutional and specialist investor market.
The placement, which was managed by ABN Amro Morgans, attracted some new institutional investors as well as existing shareholders, and was oversubscribed at close. Circadian Technologies (ASX:CIR) subscribed to approximately $1 million worth of the raising, subject to shareholder approval.
The cash will be channeled directly into further R&D into the company's multiple sclerosis therapeutic, ATL1102, and psoriasis treatment ATL1101, as well as for other drug discovery activities.
Stem cell experiments conducted in space
Scientists are one step closer to manufacturing stem cells in space — which could speed up...
Plug-and-play test evaluates T cell immunotherapy effectiveness
The plug-and-play test enables real-time monitoring of T cells that have been engineered to fight...
Common heart medicine may be causing depression
Beta blockers are unlikely to be needed for heart attack patients who have a normal pumping...
